Agrawal et al. [31] assessed 120 patients with suspected prostate cancer recurrence or disease progression based on serum PSA or clinical evaluation and found the overall sensitivity, specificity, and accuracy of 18F-NaF PET/CT in the detection of metastatic skeletal lesions to be 96.84, 69.47, and 83.16%, respectively. This evidence concerns the gene KLK3 and prostate carcinoma.